<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01670084</url>
  </required_header>
  <id_info>
    <org_study_id>MC1184</org_study_id>
    <secondary_id>NCI-2012-01061</secondary_id>
    <nct_id>NCT01670084</nct_id>
  </id_info>
  <brief_title>Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia</brief_title>
  <official_title>A Phase II Study of Combination Nilotinib and Hyper-CVAD in Patients Newly Diagnosed With Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia Blast-Phase Lymphoid Lineage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study researchers want to find out more about the side effects of a new drug for&#xD;
      Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) and chronic&#xD;
      myelogenous leukemia (CML) blastic phase (BP) and if this disease will respond better to&#xD;
      nilotinib combined with standard hyper-CVAD therapy rather than hyper-CVAD alone. Hyper-CVAD&#xD;
      is a combination of cyclophosphamide, mesna, vincristine (vincristine sulfate), doxorubicin&#xD;
      (doxorubicin hydrochloride), dexamethasone, methotrexate, cytarabine, and rituximab (only for&#xD;
      patients with cluster of differentiation [CD]20 positive disease). Researchers don't know all&#xD;
      the ways that this drug may affect people&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the clinical efficacy (2-year disease-free survival rate) of nilotinib and&#xD;
      combination chemotherapy in adult patients newly diagnosed with Philadelphia chromosome&#xD;
      positive B-cell acute lymphoblastic leukemia or blast crisis of chronic myeloid leukemia.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the 2-year overall survival rate. II. Determine the complete response (CR) rates&#xD;
      (hematological, cytogenetic, and molecular) in patients treated with this regimen.&#xD;
&#xD;
      III. Determine the CR duration in patients treated with this regimen. IV. Assess the safety&#xD;
      and toxicity of this regimen by National Cancer Institute (NCI) Common Terminology Criteria&#xD;
      for Adverse Events (CTCAE) version 4.0.&#xD;
&#xD;
      TERTIARY OBJECTIVES:&#xD;
&#xD;
      I. Assess the prognostic and predictive factors for patients treated with this regimen.&#xD;
&#xD;
      II. Assess the cerebrospinal fluid (CSF) penetration for Nilotinib (CSF Nilotinib levels) in&#xD;
      humans.&#xD;
&#xD;
      III. Assess the Abelson (ABL) kinase domain mutations frequency at diagnosis, during therapy,&#xD;
      and at relapse.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      INDUCTION AND CONSOLIDATION SCHEDULE A (COURSES 1, 3, 5, 7): Patients receive&#xD;
      cyclophosphamide intravenously (IV) twice daily (BID) over 2 hours on days 1-3, mesna IV&#xD;
      continuously on days 1-3, doxorubicin hydrochloride IV push on day 4, vincristine sulfate IV&#xD;
      on days 4 and 11, dexamethasone IV or orally (PO) on days 1-4 and 11-14, methotrexate&#xD;
      intrathecally (IT) on day 2, cytarabine IT on day 8, and nilotinib PO BID on days 1-14.&#xD;
      Patients with CD20-positive disease also receive rituximab IV on days 1 and 11.&#xD;
&#xD;
      INDUCTION AND CONSOLIDATION SCHEDULE B (COURSES 2, 4, 6, 8): Patients receive methotrexate IV&#xD;
      continuously over 24 hours on day 1, cytarabine IV over 2 hours on days 2-3, leucovorin&#xD;
      calcium IV every 6 hours on days 2-3, methotrexate IT on day 2, cytarabine IT on day 8, and&#xD;
      nilotinib PO BID on days 1-14. Patients with CD20-positive disease also receive rituximab IV&#xD;
      on days 1 and 11.&#xD;
&#xD;
      MAINTENANCE (COURSES 9-32): Patients receive nilotinib PO BID on days 1-28 (days 1-14 for&#xD;
      minimal residual disease [MRD]-positive patients), vincristine sulfate IV on day 1, and&#xD;
      prednisone PO on days 1 to 5. Patients also receive rituximab IV on day 1 of each course if&#xD;
      CD20-positive, every sixth course if MRD-negative, or every third course if MRD-positive.&#xD;
&#xD;
      INTENSIFICATION: Patients receive treatment as in Schedule A in courses 14 and 21 of&#xD;
      maintenance therapy and treatment as in Schedule B in courses 15 and 22 of maintenance&#xD;
      therapy.&#xD;
&#xD;
      DELAYED MAINTENANCE (COURSES 33-36): Patients receive nilotinib PO BID on days 1 to 84.&#xD;
      Treatment repeats every 84 days for up to 4 courses.&#xD;
&#xD;
      Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 6-12 months for 4 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No Accrual&#xD;
  </why_stopped>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival rate, defined as a patient who is alive and relapse-free, in patients who achieve a CR during the first 2 courses out to 2 years</measure>
    <time_frame>2 years</time_frame>
    <description>The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true success proportion will be calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival time, defined as the time from registration to death due to any cause out to 2 years</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response (CR) rate estimated by the number of patients achieving an objective status of CR during the first 2 courses of treatment divided by the total number of evaluable patients</measure>
    <time_frame>56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response (CR) as defined for all evaluable patients who have achieved a CR as the date at which the patient's objective status is first noted to be a CR to the earliest date relapse is documented out to 4 years</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum grade for each type of adverse event, graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0</measure>
    <time_frame>Up to 30 days after last dose of study drug</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>B-cell Adult Acute Lymphoblastic Leukemia</condition>
  <condition>Blastic Phase Chronic Myelogenous Leukemia</condition>
  <condition>Chronic Myelogenous Leukemia, BCR-ABL1 Positive</condition>
  <condition>Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia</condition>
  <condition>Untreated Adult Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (nilotinib, combination chemotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nilotinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (nilotinib, combination chemotherapy)</arm_group_label>
    <other_name>AMN 107</other_name>
    <other_name>Tasigna</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (nilotinib, combination chemotherapy)</arm_group_label>
    <other_name>IDEC-C2B8</other_name>
    <other_name>IDEC-C2B8 monoclonal antibody</other_name>
    <other_name>Mabthera</other_name>
    <other_name>MOAB IDEC-C2B8</other_name>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (nilotinib, combination chemotherapy)</arm_group_label>
    <other_name>CPM</other_name>
    <other_name>CTX</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Endoxan</other_name>
    <other_name>Endoxana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (nilotinib, combination chemotherapy)</arm_group_label>
    <other_name>ADM</other_name>
    <other_name>ADR</other_name>
    <other_name>Adria</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (nilotinib, combination chemotherapy)</arm_group_label>
    <other_name>leurocristine sulfate</other_name>
    <other_name>VCR</other_name>
    <other_name>Vincasar PFS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>Given IV or IT</description>
    <arm_group_label>Treatment (nilotinib, combination chemotherapy)</arm_group_label>
    <other_name>amethopterin</other_name>
    <other_name>Folex</other_name>
    <other_name>methylaminopterin</other_name>
    <other_name>Mexate</other_name>
    <other_name>MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <description>Given IV or IT</description>
    <arm_group_label>Treatment (nilotinib, combination chemotherapy)</arm_group_label>
    <other_name>ARA-C</other_name>
    <other_name>arabinofuranosylcytosine</other_name>
    <other_name>arabinosylcytosine</other_name>
    <other_name>Cytosar-U</other_name>
    <other_name>cytosine arabinoside</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (nilotinib, combination chemotherapy)</arm_group_label>
    <other_name>DeCortin</other_name>
    <other_name>Deltra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mesna</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (nilotinib, combination chemotherapy)</arm_group_label>
    <other_name>mercaptoethane sulfonate</other_name>
    <other_name>Mesnex</other_name>
    <other_name>MSA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Treatment (nilotinib, combination chemotherapy)</arm_group_label>
    <other_name>Aeroseb-Dex</other_name>
    <other_name>Decaderm</other_name>
    <other_name>Decadron</other_name>
    <other_name>DM</other_name>
    <other_name>DXM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (nilotinib, combination chemotherapy)</arm_group_label>
    <other_name>CF</other_name>
    <other_name>CFR</other_name>
    <other_name>LV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Untreated, histological confirmed Philadelphia positive B-cell acute lymphoblastic&#xD;
             leukemia or chronic myeloid leukemia blast-phase lymphoid lineage (bilineal,&#xD;
             biphenotypic or undifferentiated) per World Health Organization (WHO) criteria; NOTE:&#xD;
             Dexamethasone (or corticosteroids) use is allowed if needed before starting&#xD;
             chemotherapy; prior imatinib or dasatinib therapy for CML chronic phase (CP) or&#xD;
             accelerated phase (AP) is allowed&#xD;
&#xD;
          -  Molecular or cytogenetic documentation of BCR-ABL fusion gene via any of the&#xD;
             following: reverse transcriptase-polymerase chain reaction (RT-PCR), G-banding, or&#xD;
             fluorescence in situ hybridization (FISH) testing from peripheral blood and/or bone&#xD;
             marrow sampling&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2&#xD;
&#xD;
          -  Magnesium/potassium/phosphorus within normal limits (WNL)&#xD;
&#xD;
          -  Serum amylase =&lt; 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
          -  Lipase =&lt; 1.5 x ULN&#xD;
&#xD;
          -  Total bilirubin &lt; 1.5 x ULN (does not apply to patients with isolated&#xD;
             hyperbilirubinemia [e.g., Gilbert's disease], in this situation the direct bilirubin&#xD;
             =&lt; 2 x ULN)&#xD;
&#xD;
          -  Alkaline phosphatase =&lt; 3 x ULN&#xD;
&#xD;
          -  Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =&lt; 3&#xD;
             x ULN&#xD;
&#xD;
          -  Serum glutamic pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) =&lt; 3 x ULN&#xD;
&#xD;
          -  Creatinine =&lt; 1.5 x ULN&#xD;
&#xD;
          -  Negative serum pregnancy test done =&lt; 7 days prior to registration, for women of&#xD;
             childbearing potential only&#xD;
&#xD;
          -  Provide informed written consent&#xD;
&#xD;
          -  Willing to return to Mayo Clinic Rochester or Mayo Clinic Arizona for follow-up during&#xD;
             the active monitoring phase of the study&#xD;
&#xD;
          -  Willing to provide CSF and blood samples for correlative research purposes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any of the following because this study involves investigational agent(s) whose&#xD;
             genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are&#xD;
             unknown:&#xD;
&#xD;
               -  Pregnant women&#xD;
&#xD;
               -  Nursing women&#xD;
&#xD;
               -  Men or women of childbearing potential who are unwilling to employ adequate&#xD;
                  contraception throughout the study and for 3 months after completion of study&#xD;
                  treatment&#xD;
&#xD;
          -  Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment&#xD;
             of the investigator, would make the patient inappropriate for entry into this study or&#xD;
             interfere significantly with the proper assessment of safety and toxicity of the&#xD;
             prescribed regimens&#xD;
&#xD;
          -  Immunocompromised patients (other than that related to the use of corticosteroids)&#xD;
             including patients known to be human immunodeficiency virus (HIV) positive (even if on&#xD;
             highly active antiretroviral therapy [HAART])&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          -  Receiving any other investigational agent which would be considered as a treatment for&#xD;
             the primary neoplasm&#xD;
&#xD;
          -  Other active malignancy =&lt; 3 years prior to registration; EXCEPTIONS: Non-melanotic&#xD;
             skin cancer or carcinoma-in-situ of the cervix&#xD;
&#xD;
          -  History of myocardial infarction =&lt; 12 months, or congestive heart failure requiring&#xD;
             use of ongoing maintenance therapy for life-threatening ventricular arrhythmias&#xD;
&#xD;
          -  Previous treatment with chemotherapy or any other tyrosine kinase inhibitor (prior&#xD;
             imatinib or dasatinib for CML-CP/-AP is allowed)&#xD;
&#xD;
          -  Impaired cardiac function including any one of the following:&#xD;
&#xD;
               -  Inability to monitor the QT interval on electrocardiogram (ECG)&#xD;
&#xD;
               -  Congenital long QT syndrome or a known family history of long QT syndrome&#xD;
&#xD;
               -  Cardiac ejection fraction (EF) &lt; 45%&#xD;
&#xD;
               -  Clinically significant resting brachycardia (&lt; 50 beats per minute)&#xD;
&#xD;
               -  Corrected QT interval (QTc) &gt; 450 msec on baseline ECG; if QTc &gt; 450 msec and&#xD;
                  electrolytes are not within normal ranges, electrolytes should be corrected and&#xD;
                  then the patient re-screened for QTc&#xD;
&#xD;
               -  Other clinically significant uncontrolled heart disease (e.g. unstable angina,&#xD;
                  congestive heart failure or uncontrolled hypertension)&#xD;
&#xD;
               -  History of or presence of clinically significant ventricular or atrial&#xD;
                  tachyarrhythmias&#xD;
&#xD;
          -  Patients receiving any medications or substances that are strong or moderate&#xD;
             inhibitors of cytochrome P450 3A4 (CYP3A4); use of the following strong or moderate&#xD;
             inhibitors are prohibited =&lt; 7 days prior to registration:&#xD;
&#xD;
               -  Strong Inhibitors of CYP3A4; &gt; 5-fold increase in the plasma area under the curve&#xD;
                  (AUC) values or more than 80% decrease in clearance&#xD;
&#xD;
                    -  Indinavir (Crixivan®)&#xD;
&#xD;
                    -  Nelfinavir (Viracept®)&#xD;
&#xD;
                    -  Atazanavir (Reyataz®)&#xD;
&#xD;
                    -  Ritonavir (Norvir®)&#xD;
&#xD;
                    -  Clarithromycin (Biaxin®, Biaxin XL®)&#xD;
&#xD;
                    -  Itraconazole (Sporanox®)&#xD;
&#xD;
                    -  Ketoconazole (Nizoral®)&#xD;
&#xD;
                    -  Nefazodone (Serzone®)&#xD;
&#xD;
                    -  Saquinavir (Fortovase®, Invirase®)&#xD;
&#xD;
                    -  Telithromycin (Ketek®)&#xD;
&#xD;
               -  Moderate Inhibitors of CYP3A4; &gt; 2-fold increase in the plasma AUC values or&#xD;
                  50-80% decrease in clearance&#xD;
&#xD;
                    -  Aprepitant (Emend®)&#xD;
&#xD;
                    -  Erythromycin (Erythrocin®, E.E.S. ®, Ery-Tab®, Eryc®, EryPed®, PCE®)&#xD;
&#xD;
                    -  Fluconazole (Diflucan®)&#xD;
&#xD;
                    -  Grapefruit juice&#xD;
&#xD;
                    -  Verapamil (Calan®, Calan SR®, Covera-HS®, Isoptin SR®, Verelan®, Verelan&#xD;
                       PM®)&#xD;
&#xD;
                    -  Diltiazem (Cardizem®, Cardizem CD®, Cardizem LA®, Cardizem SR®, Cartia XT™,&#xD;
                       Dilacor XR®, Diltia XT®, Taztia XT™, Tiazac®)&#xD;
&#xD;
          -  Patients receiving any medications or substances that are inducers of CYP3A4; use of&#xD;
             the following inducers are prohibited =&lt; 7 days prior to registration&#xD;
&#xD;
             * Inducers of CYP3A4&#xD;
&#xD;
               -  Efavirenz (Sustiva®)&#xD;
&#xD;
               -  Nevirapine (Viramune®)&#xD;
&#xD;
               -  Carbamazepine (Carbatrol®, Epitol®, Equetro™, Tegretol®, Tegretol-XR®)&#xD;
&#xD;
               -  Modafinil (Provigil®)&#xD;
&#xD;
               -  Phenobarbital (Luminal®)&#xD;
&#xD;
               -  Phenytoin (Dilantin®, Phenytek®)&#xD;
&#xD;
               -  Pioglitazone (Actos®)&#xD;
&#xD;
               -  Rifabutin (Mycobutin®)&#xD;
&#xD;
               -  Rifampin (Rifadin®)&#xD;
&#xD;
               -  St. John's wort&#xD;
&#xD;
          -  Patients currently receiving treatment with any medications that have the potential to&#xD;
             prolong the QT interval and the treatment cannot be either discontinued or switched to&#xD;
             a different medication prior to starting study drug&#xD;
&#xD;
          -  Impaired gastrointestinal (GI) function or GI disease that may significantly alter the&#xD;
             absorption of study drug (e.g., ulcerative diseases, uncontrolled nausea, vomiting,&#xD;
             diarrhea, malabsorption syndrome, small bowel resection or gastric bypass surgery)&#xD;
&#xD;
          -  Acute or chronic pancreatic disease&#xD;
&#xD;
          -  Known cytopathologically confirmed central nervous system (CNS) infiltration&#xD;
&#xD;
          -  Acute or chronic liver disease or severe renal disease considered unrelated to the&#xD;
             cancer&#xD;
&#xD;
          -  History of significant congenital or acquired bleeding disorder unrelated to cancer&#xD;
&#xD;
          -  Major surgery =&lt; 4 weeks prior to registration or not recovered from prior surgery&#xD;
&#xD;
          -  Treatment with other investigational agents =&lt; 14 days of registration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aref Al-Kali, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>August 17, 2012</study_first_submitted>
  <study_first_submitted_qc>August 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2012</study_first_posted>
  <last_update_submitted>October 29, 2015</last_update_submitted>
  <last_update_submitted_qc>October 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Blast Crisis</mesh_term>
    <mesh_term>Philadelphia Chromosome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Mesna</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

